Rescriptor® (delavirdine) – Product discontinuation

- On June 26, 2019, the FDA announced the discontinuation of ViiV Healthcare's Rescriptor (delavirdine) 200 mg tablets.
    - The discontinuation was due to business reasons and is not due to any safety, efficacy or quality issues.
    - The anticipated final date for availability to patients is January 2020.

- Rescriptor is approved for the treatment of human immunodeficiency-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.